Stay Connected. Manage Your Care.

Access your health information anytime and anywhere, at home or on the go, with MyHealth.

Message your clinic
View your lab results

Schedule your next appointment
Pay your bill

The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.

Download the app »

View All Content for Patients & Visitors »

Guest Services

24/7

We are available to assist you

whenever you need it. Give us a call at

650-498-3333 or

GuestServices@stanfordhealthcare.org.

View All Content for Health Care Professionals »

PHYSICIAN HELPLINE

Have a question? We're here to help! Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.

REFER A PATIENT

Fax 650-320-9443

Track your patients' progress and communicate with Stanford providers conveniently and securely.

Learn more about PRISM »

Stanford Health Care (SHC) (formerly Stanford Hospital & Clinics)

Jonathan S. Berek, MD, MMS

Gynecologic oncologist

Laurie Kraus Lacob Professor

Bio: Chair, Department of Obstetrics and Gynecology

Read Full Bio

Summary
Clinical Trials
Reviews

4.9 out of 5

37 Patient Ratings
5 Patient Comments

Gynecologic Cancer Program

900 Blake Wilbur Drive
1st Floor
Palo Alto, CA 94304
Phone: 650-498-6004

More Clinic Information » Insurance Coverage »

Stanford Women's Cancer Center

900 Blake Wilbur Drive
1st Floor
Palo Alto, CA 94304
Phone: 650-498-6004

More Clinic Information » Insurance Coverage »

Cancer Immunotherapy Program

875 Blake Wilbur Drive
Palo Alto, CA 94304
Phone: 650-498-6000

More Clinic Information » Insurance Coverage »

Summary
Clinical Trials
Reviews

Practice Areas

View All 6 Practice Areas

Professional Education

Medical Education: Johns Hopkins University School of Medicine (1973) MD
Residency: Harvard Medical School Brigham and Women's Hospital (1979) MA
Internship: Harvard Medical School Brigham and Women's Hospital (1976) MA
Fellowship: UCLA - School of Medicine (1981) CA
Biomedical Sciences, Brown University, MMS (1973)
Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (1983)
Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (1982)

View All

Administrative Appointments

Director, Stanford Women's Cancer Center, Stanford Cancer Institute (2008 - Present)
Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine (2005 - Present)
Laurie Kraus Lacob Professor, Stanford (2012 - Present)

View All

Publications

Immunotherapeutic approaches to ovarian cancer treatment.
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. (2015). Immunotherapeutic approaches to ovarian cancer treatment. Journal for immunotherapy of cancer, 3, 7-?.
Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer
Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., & Longacre, T. A. (2014). Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 38(11), 1501-1509.
Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study
Berek, J. S., Edwards, R. P., Parker, L. P., DeMars, L. R., Herzog, T. J., & Krasner, C. N. (2014). Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24(9), 1583-1589.
Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53 Park, S.-H., Lee, J. H., Berek, J. S., & Hu, M. Ct. (2014). Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. INTERNATIONAL JOURNAL OF ONCOLOGY, 45(4), 1691-1698.
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation Hu, T., Chung, Y. M., Guan, M., Ma, M., Ma, J., & Hu, M. Ct. (2014). Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. SCIENTIFIC REPORTS, 4.
A statement on abortion by 100A professors of obstetrics: 40 years later Archer, D. F., Autry Amy (Meg), Barbieri, R. L., Berek, J. S., Berga, S. L., & Yankowitz, J. (2013). A statement on abortion by 100A professors of obstetrics: 40 years later. CONTRACEPTION, 88(4), 568-576.
Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study Simpkins, F., Flores, A., Chu, C., Berek, J. S., Lucci, J., & Coukos, G. (2013). Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study. CANCER IMMUNOLOGY RESEARCH, 1(3), 168-178.
In reply. Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., & Manson, Ja. E. (2013). In reply. Obstetrics and gynecology, 122(2), 396-?.
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study Sabbatini, P., Harter, P., Scambia, G., Sehouli, J., Meier, W., & Pfisterer, J. (2013). Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study. JOURNAL OF CLINICAL ONCOLOGY, 31(12), 1554-1561.
Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., & Manson, Ja. E. (2013). Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study. OBSTETRICS AND GYNECOLOGY, 121(4), 709-716.
Cancer of the ovary, fallopian tube, and peritoneum Berek, J. S., Crum, C., & Friedlander, M. (2012). Cancer of the ovary, fallopian tube, and peritoneum. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 119, S118-S129.
FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage Chung, Y. M., Park, S.-H., Tsai, W.-B., Wang, S.-Y., Ikeda, M.-A., & Hu, M. Ct. (2012). FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. NATURE COMMUNICATIONS, 3.
Current Management of Vulvar Cancer Fuh, K. C., & Berek, J. S. (2012). Current Management of Vulvar Cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 26(1), 45-?.
A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection Tian, W.-J., Chi, D. S., Sehouli, J., Trope, C. G., Jiang, R., & Harter, P. (2012). A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection. ANNALS OF SURGICAL ONCOLOGY, 19(2), 597-604.
Rethinking ovarian cancer: recommendations for improving outcomes Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., & Balkwill, F. R. (2011). Rethinking ovarian cancer: recommendations for improving outcomes. NATURE REVIEWS CANCER, 11(10), 719-725.
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort Zang, R. Y., Harter, P., Chi, D. S., Sehouli, J., Jiang, R., & Berek, J. S. (2011). Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. BRITISH JOURNAL OF CANCER, 105(7), 890-896.
Personalizing CA125 Levels for Ovarian Cancer Screening Dorigo, O., & Berek, J. S. (2011). Personalizing CA125 Levels for Ovarian Cancer Screening. CANCER PREVENTION RESEARCH, 4(9), 1356-1359.
First-Line Therapy in Ovarian Cancer Trials Thigpen, T., duBois, A., McAlpine, J., DiSaia, P., Fujiwara, K., & Stuart, G. Ce. (2011). First-Line Therapy in Ovarian Cancer Trials. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 21(4), 756-762.
Abagovomab for ovarian cancer Pfisterer, J., Harter, P., Simonelli, C., Peters, M., Berek, J., & du Bois, A. (2011). Abagovomab for ovarian cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 11(3), 395-403.
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer Grisham, R. N., Berek, J., Pfisterer, J., & Sabbatini, P. (2011). Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. IMMUNOTHERAPY, 3(2), 153-162.
Strategies and Goals: The Future of the International Gynecologic Cancer Society IGCS Presidential Address Berek, J. S. (2010). Strategies and Goals: The Future of the International Gynecologic Cancer Society IGCS Presidential Address. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 20(9), 1434-1439.
Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy Recommendations Based on Risk of Ovarian Cancer Berek, J. S., Chalas, E., Edelson, M., Moore, D. H., Burke, W. M., & Berchuck, A. (2010). Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy Recommendations Based on Risk of Ovarian Cancer. OBSTETRICS AND GYNECOLOGY, 116(3), 733-743.
Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy Nicodemus, C. F., Wang, L., Lucas, J., Varghese, B., & Berek, J. S. (2010). Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 202(6).
The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade Kandalaft, L. E., Singh, N., Liao, J. B., Facciabene, A., Berek, J. S., & Coukos, G. (2010). The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. GYNECOLOGIC ONCOLOGY, 116(2), 222-233.
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study Fleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., & Fiorica, J. V. (2010). Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 116(1), 15-20.
Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity? Berek, J. S. (2009). Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 19, S18-S20.
Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., & Manson, Ja. E. (2009). Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study. OBSTETRICS AND GYNECOLOGY, 113(5), 1027-1037.
Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience Markman, M., Brady, M., Hutson, A., & Berek, J. S. (2009). Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 19(2), 223-229.
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., & Nicodemus, C. F. (2009). Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(3), 418-425.
HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review Karam, A., Berek, J. S., Stenson, A., Rao, J., & Dorigo, O. (2008). HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. GYNECOLOGIC ONCOLOGY, 111(3), 568-571.
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007 Ashworth, A., Balkwill, F., Bast, R. C., Berek, J. S., Kaye, A., & Workman, P. (2008). Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. GYNECOLOGIC ONCOLOGY, 108(3), 652-657.
Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer Chan, J. K., Kapp, D. S., Cheung, M. K., Shin, J. Y., Stieglitz, D., & Guo, H. (2008). Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(2).
Her2neu over-expression and PI3kinase/Akt pathway activation in Paget's disease of the vulva. Stenson, A., Behjatnia, B., Shamonki, J., Rao, J., Karam, A., & Dorigo, O. (2008). Her2neu over-expression and PI3kinase/Akt pathway activation in Paget's disease of the vulva. REPRODUCTIVE SCIENCES, 15(2), 307A-307A.
Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths Ueda, S. M., Kapp, D. S., Cheung, M. K., Shin, J. Y., Osann, K., & Chan, J. K. (2008). Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(2).
CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer Berek, J. S., Taylor, P. T., & Nicodemus, C. F. (2008). CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. JOURNAL OF IMMUNOTHERAPY, 31(2), 207-214.
Elective oophorectomy in the gynecological patient: when is it desirable? Parker, W. H., Shoupe, D., Broder, M. S., Liu, Z., Farquhar, C., & Berek, J. S. (2007). Elective oophorectomy in the gynecological patient: when is it desirable?. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 19(4), 350-354.
Vulvar melanoma - A multivariable analysis of 644 patients Sugiyama, V. E., Chan, J. K., Shin, J. Y., Berek, J. S., Osann, K., & Kapp, D. S. (2007). Vulvar melanoma - A multivariable analysis of 644 patients. OBSTETRICS AND GYNECOLOGY, 110(2), 296-301.
Impact of the human papilloma vaccine on cervical cancer Chan, J. K., & Berek, J. S. (2007). Impact of the human papilloma vaccine on cervical cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(20), 2975-2982.
The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients Chan, J. K., Urban, R., Hu, J. M., Shin, J. Y., Husain, A., & Kapp, D. S. (2007). The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients. BRITISH JOURNAL OF CANCER, 96(12), 1817-1822.
Lymphadenectomy in endometrioid uterine cancer staging - How many lymph nodes are enough? A study of 11,443 patients Chan, J. K., Urban, R., Cheung, M. K., Shin, J. Y., Husain, A., & Osann, K. (2007). Lymphadenectomy in endometrioid uterine cancer staging - How many lymph nodes are enough? A study of 11,443 patients. CANCER, 109(12), 2454-2460.
Influence of the gynecologic oncologist on the survival of ovarian cancer patients Chan, J. K., Kapp, D. S., Shin, J. Y., Husain, A., Teng, N. N., & O'Malley, C. (2007). Influence of the gynecologic oncologist on the survival of ovarian cancer patients. OBSTETRICS AND GYNECOLOGY, 109(6), 1342-1350.
Ovarian conservation at the time of hysterectomy for benign disease Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., & Berek, J. S. (2007). Ovarian conservation at the time of hysterectomy for benign disease. CLINICAL OBSTETRICS AND GYNECOLOGY, 50(2), 354-361.
Elective oophorectomy for benign gynecological disorders Shoupe, D., Parker, W. H., Broder, M. S., Liu, Z., Farquhar, C., & Berek, J. S. (2007). Elective oophorectomy for benign gynecological disorders. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 14(3), 580-585.
Association of lymphadenectomy and survival in stage I ovarian cancer patients - In reply Chan, J. K., Munro, E., Cheung, M., Husain, A., Teng, N. N., & Osann, K. (2007). Association of lymphadenectomy and survival in stage I ovarian cancer patients - In reply. OBSTETRICS AND GYNECOLOGY, 109(4), 1000-1001.
Prognostic factors for uterine cancer in reproductive-aged women Lee, N. K., Cheung, M. K., Shin, J. Y., Husain, A., Teng, N. N., & Chan, J. K. (2007). Prognostic factors for uterine cancer in reproductive-aged women. OBSTETRICS AND GYNECOLOGY, 109(3), 655-662.
A multivariate analysis of vulvar melanomas: A study of 359 patients Sugiyama, V. E., Shin, J. Y., Osann, K., Kapp, D. S., Husain, A., & Chan, J. K. (2007). A multivariate analysis of vulvar melanomas: A study of 359 patients. GYNECOLOGIC ONCOLOGY, 104(3), S5-S6.
Factors responsible for the increase in death rate of women diagnosed with uterine corpus cancer Ueda, S. M., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., & Chan, J. K. (2007). Factors responsible for the increase in death rate of women diagnosed with uterine corpus cancer. GYNECOLOGIC ONCOLOGY, 104(3), S8-S8.
Access to gynecologic oncologists and its impact on survival of women with epithelial ovarian cancer Chan, J. K., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., & O'Malley, C. (2007). Access to gynecologic oncologists and its impact on survival of women with epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 104(3), S23-S23.
Racial disparities in the surgical treatment of epithelial ovarian cancer in the United States Chan, J. K., Zhang, M., Hu, J., Shin, J. Y., Husain, A., & Osann, K. (2007). Racial disparities in the surgical treatment of epithelial ovarian cancer in the United States. GYNECOLOGIC ONCOLOGY, 104(3), S31-S31.
CA125: Megadaltons of novel opportunities Dorigo, O., & Berek, J. S. (2007). CA125: Megadaltons of novel opportunities. GYNECOLOGIC ONCOLOGY, 104(3), 505-507.
Prognostic factors responsible for survival in sex cord stromal tumors of the ovary- An analysis of 376 women Zhang, M., Cheung, M. K., Shin, J. Y., Kapp, D. S., Husain, A., & Chan, J. K. (2007). Prognostic factors responsible for survival in sex cord stromal tumors of the ovary- An analysis of 376 women. GYNECOLOGIC ONCOLOGY, 104(2), 396-400.
Association of lymphadenectomy and survival in stage I ovarian cancer patients Chan, J. K., Munro, E. G., Cheung, M. K., Husain, A., Teng, N. N., & Osann, K. (2007). Association of lymphadenectomy and survival in stage I ovarian cancer patients. OBSTETRICS AND GYNECOLOGY, 109(1), 12-19.
The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma Parthasarathy, A., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., & Chan, J. K. (2006). The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. GYNECOLOGIC ONCOLOGY, 103(3), 1095-1099.
Ovarian cancer in younger vs older women: a population-based analysis Chan, J. K., Urban, R., Cheung, M. K., Osann, K., Husain, A., & Leiserowitz, G. S. (2006). Ovarian cancer in younger vs older women: a population-based analysis. BRITISH JOURNAL OF CANCER, 95(10), 1314-1320.
Response to commentaries on retention of the ovaries and long-term survival after hysterectomy Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., & Berek, J. S. (2006). Response to commentaries on retention of the ovaries and long-term survival after hysterectomy. CLIMACTERIC, 9(5), 396-398.
Patterns and progress in ovarian cancer over 14 years Chan, J. K., Cheung, M. K., Husain, A., Teng, N. N., West, D., & Osann, K. (2006). Patterns and progress in ovarian cancer over 14 years. OBSTETRICS AND GYNECOLOGY, 108(3), 521-528.
Intraperitoneal chemotherapy for ovarian cancer Hamilton, C. A., & Berek, J. S. (2006). Intraperitoneal chemotherapy for ovarian cancer. CURRENT OPINION IN ONCOLOGY, 18(5), 507-515.
The number of lymph nodes with metastatic disease portends for a poorer prognosis in women with stage IIIC-IV endometrioid uterine cancer. Chan, J. K., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., & Kapp, D. S. (2006). The number of lymph nodes with metastatic disease portends for a poorer prognosis in women with stage IIIC-IV endometrioid uterine cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 265S-265S.
The. role of extensive lymphadenectomy in stage I ovarian cancer. Munro, E. G., Lee, N. K., Cheung, M. K., Osann, K., Husain, A., & Chan, J. K. (2006). The. role of extensive lymphadenectomy in stage I ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 272S-272S.
The impact of lymphadenectomy in women with endometrioid uterine cancer: A study of 39,396 women. Lee, N. K., Wu, H., Cheung, M. K., Osann, K., Husain, A., & Chan, J. K. (2006). The impact of lymphadenectomy in women with endometrioid uterine cancer: A study of 39,396 women. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 256S-256S.
The role of surgical staging in grade 1 endometrioid corpus cancer. Chan, J. K., Guo, H., Cheung, M. K., Osann, K., Husain, A., & Kapp, D. S. (2006). The role of surgical staging in grade 1 endometrioid corpus cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 258S-258S.
Surgery for ovarian cancer: how to improve survival Bristow, R. E., & Berek, J. S. (2006). Surgery for ovarian cancer: how to improve survival. LANCET, 367(9522), 1558-1560.
10th Biennial Helene Harris Memorial Trust Meeting Balkwill, F. R., Ashworth, A., Bast, R. C., Berek, J. S., Boyd, J., & Urban, N. D. (2006). 10th Biennial Helene Harris Memorial Trust Meeting. CANCER RESEARCH, 66(6), 2904-2906.
Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium Disis, M. L., Rivkin, S. E., Baron, A., Markman, M., Connolly, D., & Berek, J. S. (2006). Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 16(2), 463-469.
An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer Bryan, D. N., Radbod, R., & Berek, J. S. (2006). An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 16(1), 125-134.
Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA Berek, J. S., Howe, C., Lagasse, L. D., & Hacker, N. F. (2005). Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA. GYNECOLOGIC ONCOLOGY, 99(1), 153-159.
Design, conduct and evaluation of a communication course for oncology fellows Lenzi, R., Baile, W. F., Berek, J., Back, A., Buckman, R., & Parker, P. A. (2005). Design, conduct and evaluation of a communication course for oncology fellows. JOURNAL OF CANCER EDUCATION, 20(3), 143-149.
Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies Elkas, J. C., Berek, J. S., Leuchter, R., Lagasse, L. D., & Karlan, B. Y. (2005). Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies. GYNECOLOGIC ONCOLOGY, 97(2), 685-692.
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial Monk, B. J., Wang, J. M., Im, S., Stock, R. J., Peters, W. A., & ALBERTS, D. S. (2005). Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. GYNECOLOGIC ONCOLOGY, 96(3), 721-728.
Monoclonal antibody therapy of ovarian cancer Nicodemus, C. F., & Berek, J. S. (2005). Monoclonal antibody therapy of ovarian cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 5(1), 87-96.
Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study Muggia, F. M., Blessing, J. A., Waggoner, S., Berek, J. S., Monk, B. J., & Pearl, M. L. (2005). Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. GYNECOLOGIC ONCOLOGY, 96(1), 108-111.
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., & Nicodemus, C. F. (2004). Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(17), 3507-3516.
Using fresh tissue dissection to teach human anatomy in the clinical years Robinson, A. G., Metten, S., Guiton, G., & Berek, J. (2004). Using fresh tissue dissection to teach human anatomy in the clinical years. ACADEMIC MEDICINE, 79(7), 711-716.
Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab Berek, J. S. (2004). Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. EXPERT OPINION ON BIOLOGICAL THERAPY, 4(7), 1159-1165.
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy Nouriani, M., Bahador, A., Berek, J. S., Cheng, J. P., Chi, D. S., & Dubeau, L. (2004). Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. CLINICAL CANCER RESEARCH, 10(8), 2681-2686.
Lymphovascular and perineural invasion in the parametria: A prognostic factor for early-stage cervical cancer Memarzadeh, S., Natarajan, S., Dandade, D. P., Ostrzega, N., Saber, P. A., & Berek, J. S. (2003). Lymphovascular and perineural invasion in the parametria: A prognostic factor for early-stage cervical cancer. OBSTETRICS AND GYNECOLOGY, 102(3), 612-619.
Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust Balkwill, F., Bast, R. C., Berek, J., Chenevix-Trench, G., Gore, M., & Smyth, J. (2003). Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust. EUROPEAN JOURNAL OF CANCER, 39(13), 1818-1827.
Cervical cancer: An opportunity to prevent and cure Berek, J. S. (2003). Cervical cancer: An opportunity to prevent and cure. CANCER JOURNAL, 9(5), 325-326.
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies Gold, M. A., Walker, J. L., Berek, J. S., Hallum, A. V., Garcia, D. J., & ALBERTS, D. S. (2003). Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. GYNECOLOGIC ONCOLOGY, 90(2), 325-330.
Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study Fracasso, P. M., Blessing, J. A., Wolf, J., Rocereto, T. F., Berek, J. S., & Waggoner, S. (2003). Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 90(1), 177-180.
Progress in the management of gynecologic cancer: consensus summary statement. Cannistra, S. A., Bast, R. C., Berek, J. S., Bookman, M. A., Crum, C. P., & King, L. (2003). Progress in the management of gynecologic cancer: consensus summary statement. Journal of clinical oncology , 21(10), 129s-132s.
Biologic and immunologic therapies for ovarian cancer. Berek, J. S., Schultes, B. C., & Nicodemus, C. F. (2003). Biologic and immunologic therapies for ovarian cancer. Journal of clinical oncology , 21(10), 168s-174s.
Surgical resection of solitary brain metastasis from cervical cancer Tajran, D., & Berek, J. S. (2003). Surgical resection of solitary brain metastasis from cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(3), 368-370.
The use of continuous infusion topotecan in persistent and recurrent ovarian cancer Elkas, J. C., Holschneider, C. H., Katz, B., Li, A. J., Louie, R., & Berek, J. S. (2003). The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(2), 138-141.
CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer Memarzadeh, S., Lee, S. B., Berek, J. S., & Farias-Eisner, R. (2003). CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(2), 120-124.
Simplification of the new Bethesda 2001 classification System Berek, J. S. (2003). Simplification of the new Bethesda 2001 classification System. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 188(3), S2-S5.
Specific keynote: Immunological therapy for ovarian cancer Berek, J. S., Dorigo, O., Schultes, B., & Nicodemus, C. (2003). Specific keynote: Immunological therapy for ovarian cancer. GYNECOLOGIC ONCOLOGY, 88(1), S105-S109.
FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival Memarzadeh, S., Holschneider, C. H., Bristow, R. E., JONES, N. L., Fu, Y. S., & Farias-Eisner, R. (2002). FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 12(5), 454-458.
Advances in the management of epithelial ovarian cancer Memarzadeh, S., & Berek, J. S. (2001). Advances in the management of epithelial ovarian cancer. JOURNAL OF REPRODUCTIVE MEDICINE, 46(7), 621-629.
A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature Ghosh, K., Dorigo, O., Bristow, R., & Berek, J. (2000). A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 191(2), 212-215.
Interferon plus chemotherapy for primary treatment of ovarian cancer Berek, J. S. (2000). Interferon plus chemotherapy for primary treatment of ovarian cancer. LANCET, 356(9223), 6-7.
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., & Willemse, P. H. (2000). [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynécologie, obstétrique & fertilité, 28(7-8), 576-583.
Ovarian cancer: Epidemiology, biology, and prognostic factors Holschneider, C. H., & Berek, J. S. (2000). Ovarian cancer: Epidemiology, biology, and prognostic factors. SEMINARS IN SURGICAL ONCOLOGY, 19(1), 3-10.
Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125 Berek, J. S. (2000). Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125. GYNECOLOGIC ONCOLOGY, 77(2), 225-226.
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix Peters, W. A., Liu, P. Y., Barrett, R. J., Stock, R. J., Monk, B. J., & ALBERTS, D. S. (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. JOURNAL OF CLINICAL ONCOLOGY, 18(8), 1606-1613.
Fraud. What is the evidence? Berek, J., Gutierrez, N., Stone, J., & Testa, L. (2000). Fraud. What is the evidence?. Care management journals : Journal of case management ; The journal of long term home health care, 2(1), 44-53.
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., & Parker, S. E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. JOURNAL OF IMMUNOLOGY, 163(12), 6378-6385.
Endometrial cancer: Recent developments in evaluation and treatment Chen, L. M., McGonigle, K. F., & Berek, J. S. (1999). Endometrial cancer: Recent developments in evaluation and treatment. ONCOLOGY-NEW YORK, 13(12), 1665-?.
Recurrent mature cystic teratoma presenting as a perihepatic mass Chen, L. M., Nelson, S. D., & Berek, J. S. (1999). Recurrent mature cystic teratoma presenting as a perihepatic mass. OBSTETRICS AND GYNECOLOGY, 94(5), 856-856.
Intraperitoneal interferon-alpha in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study Berek, J. S., Markman, M., Stonebraker, B., Lentz, S. S., Adelson, M. D., & Moore, D. (1999). Intraperitoneal interferon-alpha in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 75(1), 10-14.
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study Berek, J. S., Markman, M., Blessing, J. A., Kucera, P. R., Nelson, B. E., & Hanjani, P. (1999). Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 74(1), 48-52.
Advanced epithelial ovarian cancer: 1998 consensus statements Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., & Willemse, P. Hb. (1999). Advanced epithelial ovarian cancer: 1998 consensus statements. ANNALS OF ONCOLOGY, 10, 87-92.
Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? HAMILTON, T. C., Berek, J. S., & Kaye, S. B. (1999). Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?. ANNALS OF ONCOLOGY, 10, 69-73.
Surgery during chemotherapy and at relapse of ovarian cancer Berek, J. S., Trope, C., & Vergote, I. (1999). Surgery during chemotherapy and at relapse of ovarian cancer. ANNALS OF ONCOLOGY, 10, 3-7.
A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study Feun, L. G., Blessing, J. A., Major, F. J., Disaia, P. J., Alvarez, R. D., & Berek, J. S. (1998). A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study. GYNECOLOGIC ONCOLOGY, 71(3), 410-415.
Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., & Fakhrai, H. (1998). Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. GYNECOLOGIC ONCOLOGY, 71(2), 204-210.
Psammocarcinoma with an aggressive course Poggi, S. H., Bristow, R. E., Nieberg, R. K., & Berek, J. S. (1998). Psammocarcinoma with an aggressive course. OBSTETRICS AND GYNECOLOGY, 92(4), 659-661.
Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a randomized trial testing an intensive follow-up protocol and economic incentives Marcus, A. C., Kaplan, C. P., Crane, L. A., Berek, J. S., Bernstein, G., & McClatchey, M. W. (1998). Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a randomized trial testing an intensive follow-up protocol and economic incentives. MEDICAL CARE, 36(3), 397-410.
Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. Kim, Y. B., Ghosh, K., Ainbinder, S., & Berek, J. S. (1998). Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. Cancer treatment and research, 95, 253-276.
Chemotherapy for ovarian cancer Berek, J. S., Markman, M., McGuire, W. P., Thigpen, J. T., & OZOLS, R. F. (1998). Chemotherapy for ovarian cancer. NEW INSIGHTS IN GYNECOLOGY & OBSTETRICS, 211-218.
Progress in ovarian cancer Chen, L., & Berek, J. S. (1998). Progress in ovarian cancer. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 10(1), 51-56.
Conclusions and recommendations from the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer, May 10-14, 1997, Los Angeles, California, USA Sharp, F., Blackett, A. D., Berek, J. S., & Bast, R. C. (1997). Conclusions and recommendations from the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer, May 10-14, 1997, Los Angeles, California, USA. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(5), 416-424.
Gene therapy for ovarian cancer: Development of novel treatment strategies Dorigo, O., & Berek, J. S. (1997). Gene therapy for ovarian cancer: Development of novel treatment strategies. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(1), 1-13.
Dysgerminoma: The role of conservative surgery Casey, A. C., Bhodauria, S., Shapter, A., NIEBERG, R., Barek, J. S., & FARIASEISNER, R. (1996). Dysgerminoma: The role of conservative surgery. GYNECOLOGIC ONCOLOGY, 63(3), 352-357.
Complete debulking of epithelial ovarian cancer. Berek, J. S. (1996). Complete debulking of epithelial ovarian cancer. cancer journal from Scientific American, 2(3), 132-133.
Mixed mesodermal sarcoma of the ovary in a young patient Fowler, J. M., Nathan, L., Nieberg, R. K., & Berek, J. S. (1996). Mixed mesodermal sarcoma of the ovary in a young patient. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 65(2), 249-253.
Evidence for a unifocal origin in familial ovarian cancer Gallion, H. H., Guarino, D., DePriest, P. D., VANNAGELL, J. R., Vaccarello, L., & Pieretti, M. (1996). Evidence for a unifocal origin in familial ovarian cancer. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 174(4), 1102-1106.
Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma Kim, Y. B., Berek, J. S., MARTINEZMAZA, O., & Satyaswaroop, P. G. (1996). Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. GYNECOLOGIC ONCOLOGY, 61(1), 97-100.
Complications of pelvic radiation therapy for gynecologic malignancies in elderly women McGonigle, K. F., Lavey, R. S., Juillard, G., & Berek, J. S. (1996). Complications of pelvic radiation therapy for gynecologic malignancies in elderly women. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 6(2), 149-155.
OVARIAN-CANCER SCREENING - THE USE OF SERIAL COMPLEMENTARY TUMOR-MARKERS TO IMPROVE SENSITIVITY AND SPECIFICITY FOR EARLY DETECTION Berek, J. S., & Bast, R. C. (1995). OVARIAN-CANCER SCREENING - THE USE OF SERIAL COMPLEMENTARY TUMOR-MARKERS TO IMPROVE SENSITIVITY AND SPECIFICITY FOR EARLY DETECTION. CANCER, 76(10), 2092-2096.
CONCLUSIONS AND RECOMMENDATIONS FROM THE HELENE-HARRIS-MEMORIAL-TRUST 5TH BIENNIAL INTERNATIONAL FORUM ON OVARIAN-CANCER, MAY 4-7, 1995, GLASGOW, UK Sharp, F., Blackett, A. D., Leake, R. E., & Berek, J. S. (1995). CONCLUSIONS AND RECOMMENDATIONS FROM THE HELENE-HARRIS-MEMORIAL-TRUST 5TH BIENNIAL INTERNATIONAL FORUM ON OVARIAN-CANCER, MAY 4-7, 1995, GLASGOW, UK. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 5(6), 449-458.
RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER Berek, J. S. (1995). RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32(5), 1543-1544.
OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME Berek, J. S. (1995). OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME. LANCET, 346(8969), 200-200.
ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., & Woodward, J. (1995). ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY. JOURNAL OF CLINICAL ONCOLOGY, 13(7), 1589-1599.
INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE Berek, J. S. (1995). INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE. NEW ENGLAND JOURNAL OF MEDICINE, 332(10), 675-677.
INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL Braly, P. S., Berek, J. S., Blessing, J. A., Homesley, H. D., & Averette, H. (1995). INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL. GYNECOLOGIC ONCOLOGY, 56(2), 164-168.
Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK. Sharp, F., Blackett, A. D., Leake, R. E., & Berek, J. S. (1995). Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 5(6), 449-458.
A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN Parker, W. H., Levine, R. L., Howard, F. M., SANSONE, B., & Berek, J. S. (1994). A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 179(6), 733-737.
PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS Parker, W. H., & Berek, J. S. (1994). PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS. OBSTETRICS AND GYNECOLOGY, 84(5), 897-897.
CYTOTOXICITY OF NEW AZA-ALKYL LYSOPHOSPHOLIPIDS AGAINST DRUG-SENSITIVE AND RESISTANT HUMAN OVARIAN TUMOR-CELL LINES - ROLE OF FREE-RADICALS AND POTENTIATION OF CYTOTOXICITY BY TNF-ALPHA AND CDDP Hourizadeh, A., Broquet, C., MENCIAHUERTA, J. M., BRAQUET, P., Berek, J., & Bonavida, B. (1994). CYTOTOXICITY OF NEW AZA-ALKYL LYSOPHOSPHOLIPIDS AGAINST DRUG-SENSITIVE AND RESISTANT HUMAN OVARIAN TUMOR-CELL LINES - ROLE OF FREE-RADICALS AND POTENTIATION OF CYTOTOXICITY BY TNF-ALPHA AND CDDP. ONCOLOGY REPORTS, 1(6), 1253-1259.
THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY FARIASEISNER, R., Teng, F., Oliveira, M., Leuchter, R., Karlan, B., & Berek, J. S. (1994). THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY. GYNECOLOGIC ONCOLOGY, 55(1), 108-110.
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. Casey, A. C., & Berek, J. S. (1994). Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. Obstetrics and gynecology, 84(4), 724-726.
Advances in the biology of gynecologic cancer. Gotlieb, W. H., & Berek, J. S. (1994). Advances in the biology of gynecologic cancer. Current opinion in oncology, 6(5), 513-518.
SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY Broun, E. R., Belinson, J. L., Berek, J. S., McIntosh, D., Hurd, D., & Williams, S. (1994). SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY. GYNECOLOGIC ONCOLOGY, 54(2), 142-146.
SURGICAL-MANAGEMENT OF OVARIAN-CANCER FARIASEISNER, R., Kim, Y. B., & Berek, J. S. (1994). SURGICAL-MANAGEMENT OF OVARIAN-CANCER. SEMINARS IN SURGICAL ONCOLOGY, 10(4), 268-275.
MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER Berek, J. S., & MARTINEZMAZA, T. (1994). MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER. JOURNAL OF REPRODUCTIVE MEDICINE, 39(4), 241-248.
CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA Gotlieb, W. H., Watson, J. M., Rezai, A., Johnson, M., MARTINEZMAZA, O., & Berek, J. S. (1994). CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 170(4), 1121-1130.
CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE FARIASEISNER, R., Cirisano, F. D., GROUSE, D., Leuchter, R. S., Karlan, B. Y., & Berek, J. S. (1994). CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE. GYNECOLOGIC ONCOLOGY, 53(1), 55-58.
THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., & Berek, J. S. (1994). THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 170(4), 974-980.
LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS Parker, W. H., & Berek, J. S. (1994). LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 21(1), 79-92.
UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA Parker, W. H., Fu, Y. S., & Berek, J. S. (1994). UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA. OBSTETRICS AND GYNECOLOGY, 83(3), 414-418.
Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis. Fowler, J. M., Nieberg, R. K., Schooler, T. A., & Berek, J. S. (1994). Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 4(1), 43-51.
PERITONEAL ADENOCARCINOMA (SEROUS) OF MULLERIAN TYPE - A SUBGROUP OF WOMEN PRESENTING WITH PERITONEAL CARCINOMATOSIS Fowler, J. M., Nieberg, R. K., SCHOOLER, T. A., & Berek, J. S. (1994). PERITONEAL ADENOCARCINOMA (SEROUS) OF MULLERIAN TYPE - A SUBGROUP OF WOMEN PRESENTING WITH PERITONEAL CARCINOMATOSIS. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 4(1), 43-51.
Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study Parker, W. H., Levine, R. L., Howard, F. M., Sansone, B., & Berek, J. S. (1994). Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study. The Journal of the American Association of Gynecologic Laparoscopists, 1(4, Part 2), S27.
Fine-needle aspiration cytology in the management of gynecologic oncology patients. Layfield, L. J., & Berek, J. S. (1994). Fine-needle aspiration cytology in the management of gynecologic oncology patients. Cancer treatment and research, 70, 1-13.
CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 BY HUMAN OVARIAN SURFACE EPITHELIAL-CELLS LIDOR, Y. J., Xu, F. J., MARTINEZMAZA, O., Olt, G. J., Marks, J. R., & Bast, R. C. (1993). CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 BY HUMAN OVARIAN SURFACE EPITHELIAL-CELLS. EXPERIMENTAL CELL RESEARCH, 207(2), 332-339.
PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA (A GYNECOLOGIC-ONCOLOGY-GROUP-STUDY) Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., & MORTEL, R. (1993). PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA (A GYNECOLOGIC-ONCOLOGY-GROUP-STUDY). GYNECOLOGIC ONCOLOGY, 49(3), 279-283.
IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS Herbst, A. L., & Berek, J. S. (1993). IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 168(6), 1980-1985.
GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES Watson, J. M., Berek, J. S., & MARTINEZMAZA, O. (1993). GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES. GYNECOLOGIC ONCOLOGY, 49(1), 8-15.
SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN FARIASEISNER, R., Braly, P., & Berek, J. S. (1993). SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN. GYNECOLOGIC ONCOLOGY, 48(3), 338-341.
PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE Monk, B. J., NIEBERG, R., & Berek, J. S. (1993). PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE. GYNECOLOGIC ONCOLOGY, 48(3), 389-393.
SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR-CELL LINES TO COMBINED EFFECTS OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND DOXORUBICIN - FAILURE OF THE COMBINATION TO MODULATE THE MDR PHENOTYPE Safrit, J. T., Berek, J. S., & Bonavida, B. (1993). SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR-CELL LINES TO COMBINED EFFECTS OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND DOXORUBICIN - FAILURE OF THE COMBINATION TO MODULATE THE MDR PHENOTYPE. GYNECOLOGIC ONCOLOGY, 48(2), 214-220.
Current management of invasive squamous carcinoma of the vulva. Farias-Eisner, R., & Berek, J. S. (1993). Current management of invasive squamous carcinoma of the vulva. Clinics in geriatric medicine, 9(1), 131-143.
MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER Berek, J. S., MARTINEZMAZA, O., Hamilton, T., Trope, C., Kaern, J., & Rustin, G. Js. (1993). MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER. ANNALS OF ONCOLOGY, 4, 3-16.
Advanced ovarian cancer. Tumour markers. Rustin, G. J., Van der Burg, M. E., & Berek, J. S. (1993). Advanced ovarian cancer. Tumour markers. Annals of oncology , 4, 71-77.
ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS Allen, D. G., Baak, J., Belpomme, D., Berek, J. S., Bertelsen, K., & DeVries, E. Ge. (1993). ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS. ANNALS OF ONCOLOGY, 4, 83-88.
PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS Gotlieb, W. H., Abrams, J. S., Watson, J. M., VELU, T. J., Berek, J. S., & MARTINEZMAZA, O. (1992). PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS. CYTOKINE, 4(5), 385-390.
BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER Bookman, M. A., & Berek, J. S. (1992). BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 6(4), 941-965.
INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON Berek, J. S. (1992). INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON. EUROPEAN JOURNAL OF CANCER, 28A(4-5), 719-721.
CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER UNRESPONSIVE TO CISPLATIN-BASED IP CHEMOTHERAPY - LESSONS LEARNED FROM A GYNECOLOGIC ONCOLOGY GROUP PHASE-II TRIAL OF IP CISPLATIN AND RECOMBINANT ALPHA-INTERFERON Markman, M., Berek, J. S., Blessing, J. A., McGuire, W. P., Bell, J., & Homesley, H. D. (1992). CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER UNRESPONSIVE TO CISPLATIN-BASED IP CHEMOTHERAPY - LESSONS LEARNED FROM A GYNECOLOGIC ONCOLOGY GROUP PHASE-II TRIAL OF IP CISPLATIN AND RECOMBINANT ALPHA-INTERFERON. GYNECOLOGIC ONCOLOGY, 45(1), 3-8.
IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS - RESULTS FROM A LARGE CLINIC-BASED TRIAL OF 3 INTERVENTION STRATEGIES Marcus, A. C., Crane, L. A., Kaplan, C. P., READING, A. E., Savage, E., & Berek, J. S. (1992). IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS - RESULTS FROM A LARGE CLINIC-BASED TRIAL OF 3 INTERVENTION STRATEGIES. MEDICAL CARE, 30(3), 216-230.
STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1, INTERLEUKIN-6, AND TUMOR-NECROSIS-FACTOR-ALPHA Wu, S., Rodabaugh, K., MARTINEZMAZA, O., Watson, J. M., Silberstein, D. S., & Bast, R. C. (1992). STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1, INTERLEUKIN-6, AND TUMOR-NECROSIS-FACTOR-ALPHA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 166(3), 997-1007.
EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX McGonigle, K. F., & Berek, J. S. (1992). EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 4(1), 109-119.
2ND-LOOK VERSUS 2ND NATURE Berek, J. S. (1992). 2ND-LOOK VERSUS 2ND NATURE. GYNECOLOGIC ONCOLOGY, 44(1), 1-2.
Interleukin 6 and cancer treatment. Martínez-Maza, O., & Berek, J. S. (1991). Interleukin 6 and cancer treatment. In vivo , 5(6), 583-588.
CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION-THERAPY FOR ADVANCED-STAGE SQUAMOUS CARCINOMA OF THE VULVA Berek, J. S., HEAPS, J. M., Fu, Y. S., Juillard, G. Jf., & Hacker, N. F. (1991). CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION-THERAPY FOR ADVANCED-STAGE SQUAMOUS CARCINOMA OF THE VULVA. GYNECOLOGIC ONCOLOGY, 42(3), 197-201.
ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN Shih, S., Vetto, J. T., Berek, J. S., HEAPS, J. M., & Hiatt, J. R. (1991). ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN. AMERICAN SURGEON, 57(5), 327-329.
CORRELATION OF ENDOCERVICAL CURETTAGE WITH SUBSEQUENT CONE BIOPSY IN THE INVESTIGATION OF ABNORMAL CERVICAL CYTOLOGY TAKAMI, C. Y., Nieberg, R. K., & Berek, J. S. (1991). CORRELATION OF ENDOCERVICAL CURETTAGE WITH SUBSEQUENT CONE BIOPSY IN THE INVESTIGATION OF ABNORMAL CERVICAL CYTOLOGY. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1(3), 97-103.
ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR CARCINOMA RELATIVE TO PROGNOSTIC FACTORS FOR SURVIVAL (A GYNECOLOGIC ONCOLOGY GROUP-STUDY) Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., & MORTEL, R. (1991). ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR CARCINOMA RELATIVE TO PROGNOSTIC FACTORS FOR SURVIVAL (A GYNECOLOGIC ONCOLOGY GROUP-STUDY). AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 164(4), 997-1004.
SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., & MARTINEZMAZA, O. (1991). SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 164(4), 1038-1043.
A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA-INTERFERON IN PATIENTS WITH PERSISTENT EPITHELIAL OVARIAN-CANCER Berek, J. S., WELANDER, C., Schink, J. C., Grossberg, H., Montz, F. J., & ZIGELBOIM, J. (1991). A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA-INTERFERON IN PATIENTS WITH PERSISTENT EPITHELIAL OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 40(3), 237-243.
FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS Layfield, L. J., HEAPS, J. M., & Berek, J. S. (1991). FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS. GYNECOLOGIC ONCOLOGY, 40(1), 70-73.
SURGICAL STAGING OF CERVICAL-CANCER HEAPS, J. M., & Berek, J. S. (1990). SURGICAL STAGING OF CERVICAL-CANCER. CLINICAL OBSTETRICS AND GYNECOLOGY, 33(4), 852-863.
RESISTANCE OF HUMAN OVARIAN-CANCER CELLS TO TUMOR-NECROSIS-FACTOR AND LYMPHOKINE-ACTIVATED KILLER-CELLS - CORRELATION WITH EXPRESSION OF HER2 NEU ONCOGENES Lichtenstein, A., Berenson, J., Gera, J. F., Waldburger, K., MARTINEZMAZA, O., & Berek, J. S. (1990). RESISTANCE OF HUMAN OVARIAN-CANCER CELLS TO TUMOR-NECROSIS-FACTOR AND LYMPHOKINE-ACTIVATED KILLER-CELLS - CORRELATION WITH EXPRESSION OF HER2 NEU ONCOGENES. CANCER RESEARCH, 50(22), 7364-7370.
MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN BY OPERATIVE LAPAROSCOPY - A PILOT-STUDY Parker, W. H., & Berek, J. S. (1990). MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN BY OPERATIVE LAPAROSCOPY - A PILOT-STUDY. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 163(5), 1574-1577.
CONSTITUTIVE PRODUCTION OF INTERLEUKIN-6 BY OVARIAN-CANCER CELL-LINES AND BY PRIMARY OVARIAN TUMOR CULTURES Watson, J. M., Sensintaffar, J. L., Berek, J. S., & MARTINEZMAZA, O. (1990). CONSTITUTIVE PRODUCTION OF INTERLEUKIN-6 BY OVARIAN-CANCER CELL-LINES AND BY PRIMARY OVARIAN TUMOR CULTURES. CANCER RESEARCH, 50(21), 6959-6965.
INTRAPERITONEAL ADOPTIVE IMMUNOTHERAPY FOR PERITONEAL CANCER Berek, J. S. (1990). INTRAPERITONEAL ADOPTIVE IMMUNOTHERAPY FOR PERITONEAL CANCER. JOURNAL OF CLINICAL ONCOLOGY, 8(10), 1610-1612.
OVARIAN METASTASES ARE RARE IN STAGE-I ADENOCARCINOMA OF THE CERVIX Brown, J. V., Fu, Y. S., & Berek, J. S. (1990). OVARIAN METASTASES ARE RARE IN STAGE-I ADENOCARCINOMA OF THE CERVIX. OBSTETRICS AND GYNECOLOGY, 76(4), 623-623.
SYNERGY IS DOCUMENTED INVITRO WITH LOW-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR, CISPLATIN, AND DOXORUBICIN IN OVARIAN-CANCER CELLS Bonavida, B., Tsuchitani, T., ZIGHELBOIM, J., & Berek, J. S. (1990). SYNERGY IS DOCUMENTED INVITRO WITH LOW-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR, CISPLATIN, AND DOXORUBICIN IN OVARIAN-CANCER CELLS. GYNECOLOGIC ONCOLOGY, 38(3), 333-339.
SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA HEAPS, J. M., Fu, Y. S., Montz, F. J., Hacker, N. F., & Berek, J. S. (1990). SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA. GYNECOLOGIC ONCOLOGY, 38(3), 309-314.
PATHOPHYSIOLOGY AND MANAGEMENT OF ENDOMETRIAL HYPERPLASIA AND CARCINOMA Fu, Y. S., Gambone, J. C., Do, & Berek, J. S. (1990). PATHOPHYSIOLOGY AND MANAGEMENT OF ENDOMETRIAL HYPERPLASIA AND CARCINOMA. WESTERN JOURNAL OF MEDICINE, 153(1), 50-61.
MALIGNANT NEOPLASMS ARISING IN ENDOMETRIOSIS HEAPS, J. M., Nieberg, R. K., & Berek, J. S. (1990). MALIGNANT NEOPLASMS ARISING IN ENDOMETRIOSIS. OBSTETRICS AND GYNECOLOGY, 75(6), 1023-1028.
CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER - CARDIOVASCULAR EVALUATION WITH PULMONARY-ARTERY CATHETERS EISNER, R. F., Montz, F. J., & Berek, J. S. (1990). CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER - CARDIOVASCULAR EVALUATION WITH PULMONARY-ARTERY CATHETERS. GYNECOLOGIC ONCOLOGY, 37(3), 311-314.
PHASE-II STUDY OF N-METHYLFORMAMIDE (N-MF) (NSC 3051) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY McGuire, W. P., Blessing, J. A., Berek, J. S., & Munoz, A. (1990). PHASE-II STUDY OF N-METHYLFORMAMIDE (N-MF) (NSC 3051) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. INVESTIGATIONAL NEW DRUGS, 8(2), 191-194.
ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER Berek, J. S. (1990). ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER. NEW ENGLAND JOURNAL OF MEDICINE, 322(15), 1076-1078.
RISK-FACTORS FOR THE DEVELOPMENT OF LYMPH-NODE METASTASIS IN VULVAR SQUAMOUS-CELL CARCINOMA Binder, S. W., Huang, I., Fu, Y. S., Hacker, N. F., & Berek, J. S. (1990). RISK-FACTORS FOR THE DEVELOPMENT OF LYMPH-NODE METASTASIS IN VULVAR SQUAMOUS-CELL CARCINOMA. GYNECOLOGIC ONCOLOGY, 37(1), 9-16.
AUGMENTATION OF CYTOTOXICITY OF LYMPHOKINE ACTIVATED KILLER-CELLS ON OVARIAN TUMOR-CELLS BY VARIOUS BIOLOGICAL RESPONSE MODIFIERS Nio, Y., ZIGHELBOIM, J., Berek, J. S., & Bonavida, B. (1990). AUGMENTATION OF CYTOTOXICITY OF LYMPHOKINE ACTIVATED KILLER-CELLS ON OVARIAN TUMOR-CELLS BY VARIOUS BIOLOGICAL RESPONSE MODIFIERS. ANTICANCER RESEARCH, 10(2A), 441-446.
PELVIC HEMANGIOPERICYTOMAS - A REPORT OF 5 CASES AND LITERATURE-REVIEW Munoz, A. K., Berek, J. S., Fu, Y. S., & HEINTZ, P. Am. (1990). PELVIC HEMANGIOPERICYTOMAS - A REPORT OF 5 CASES AND LITERATURE-REVIEW. GYNECOLOGIC ONCOLOGY, 36(3), 380-382.
CYCLOHEXIMIDE-INDUCED MODULATION OF TNF-MEDIATED CYTOTOXICITY IN SENSITIVE AND RESISTANT OVARIAN TUMOR-CELLS Nio, Y., ZIGHELBOIM, J., Berek, J., & Bonavida, B. (1990). CYCLOHEXIMIDE-INDUCED MODULATION OF TNF-MEDIATED CYTOTOXICITY IN SENSITIVE AND RESISTANT OVARIAN TUMOR-CELLS. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 26(1), 1-8.
RESECTION OF DIAPHRAGMATIC PERITONEUM AND MUSCLE - ROLE IN CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER Montz, F. J., Schlaerth, J. B., & Berek, J. S. (1989). RESECTION OF DIAPHRAGMATIC PERITONEUM AND MUSCLE - ROLE IN CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 35(3), 338-340.
Screening, diagnosis, and monitoring of gynecologic malignancies. Montz, F. J., & Berek, J. S. (1989). Screening, diagnosis, and monitoring of gynecologic malignancies. Current opinion in oncology, 1(1), 75-81.
SYNERGISTIC EFFECT OF COMBINED INTRAPERITONEAL CISPLATIN AND CYTOSINE-ARABINOSIDE IN A MURINE OVARIAN-CANCER MODEL Berek, J. S., Schink, J. C., & Knox, R. M. (1989). SYNERGISTIC EFFECT OF COMBINED INTRAPERITONEAL CISPLATIN AND CYTOSINE-ARABINOSIDE IN A MURINE OVARIAN-CANCER MODEL. OBSTETRICS AND GYNECOLOGY, 74(4), 663-666.
HUMAN NEUTROPHIL-MEDIATED LYSIS OF OVARIAN-CANCER CELLS Lichtenstein, A., Seelig, M., Berek, J., & ZIGHELBOIM, J. (1989). HUMAN NEUTROPHIL-MEDIATED LYSIS OF OVARIAN-CANCER CELLS. BLOOD, 74(2), 805-809.
CYTO-TOXIC AND CYTOSTATIC EFFECTS OF THE STREPTOCOCCAL PREPARATION OK-432 AND ITS SUBCELLULAR-FRACTIONS ON HUMAN OVARIAN TUMOR-CELLS Nio, Y., ZIGHELBOIM, J., Berek, J., & Bonavida, B. (1989). CYTO-TOXIC AND CYTOSTATIC EFFECTS OF THE STREPTOCOCCAL PREPARATION OK-432 AND ITS SUBCELLULAR-FRACTIONS ON HUMAN OVARIAN TUMOR-CELLS. CANCER, 64(2), 434-441.
UTILIZATION OF A MURINE MODEL TO OPTIMIZE VOLUME AND DWELL TIME OF INTRAPERITONEAL CISPLATIN Pretorius, R. G., Eisenkop, S., Berek, J. S., Hacker, N. F., Ashikaga, T., & Lagasse, L. D. (1989). UTILIZATION OF A MURINE MODEL TO OPTIMIZE VOLUME AND DWELL TIME OF INTRAPERITONEAL CISPLATIN. GYNECOLOGIC ONCOLOGY, 34(1), 66-69.
SYNCHRONOUS PRIMARY NEOPLASMS OF THE FEMALE REPRODUCTIVE-TRACT EISNER, R. F., Nieberg, R. K., & Berek, J. S. (1989). SYNCHRONOUS PRIMARY NEOPLASMS OF THE FEMALE REPRODUCTIVE-TRACT. GYNECOLOGIC ONCOLOGY, 33(3), 335-339.
LYMPHOCYTE-ACTIVATION BY RECOMBINANT INTERLEUKIN-2 IN OVARIAN-CANCER PATIENTS Boyer, P. J., Berek, J. S., & ZIGHELBOIM, J. (1989). LYMPHOCYTE-ACTIVATION BY RECOMBINANT INTERLEUKIN-2 IN OVARIAN-CANCER PATIENTS. OBSTETRICS AND GYNECOLOGY, 73(5), 793-797.
VULVOVAGINAL MELANOMA - REPORT OF 7 CASES AND LITERATURE-REVIEW Brand, E., Fu, Y. S., Lagasse, L. D., & Berek, J. S. (1989). VULVOVAGINAL MELANOMA - REPORT OF 7 CASES AND LITERATURE-REVIEW. GYNECOLOGIC ONCOLOGY, 33(1), 54-60.
RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE PLUS CISPLATIN WITH OR WITHOUT DOXORUBICIN IN OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., & MORTEL, R. (1989). RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE PLUS CISPLATIN WITH OR WITHOUT DOXORUBICIN IN OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. JOURNAL OF CLINICAL ONCOLOGY, 7(4), 457-465.
PERITONEAL CYTOLOGY OF OVARIAN-CANCER PATIENTS RECEIVING INTRAPERITONEAL THERAPY - QUANTITATION OF MALIGNANT-CELLS AND RESPONSE Sagae, S., Berek, J. S., Fu, Y. S., Chang, N., Dauplat, J., & Hacker, N. F. (1988). PERITONEAL CYTOLOGY OF OVARIAN-CANCER PATIENTS RECEIVING INTRAPERITONEAL THERAPY - QUANTITATION OF MALIGNANT-CELLS AND RESPONSE. OBSTETRICS AND GYNECOLOGY, 72(5), 782-788.
INTRAPERITONEAL ADMINISTRATION OF HUMAN RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH OVARIAN-CANCER - EFFECTS ON LYMPHOCYTE PHENOTYPE AND CYTO-TOXICITY Lichtenstein, A., Spina, C., Berek, J. S., Jung, T., & ZIGHELBOIM, J. (1988). INTRAPERITONEAL ADMINISTRATION OF HUMAN RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH OVARIAN-CANCER - EFFECTS ON LYMPHOCYTE PHENOTYPE AND CYTO-TOXICITY. CANCER RESEARCH, 48(20), 5853-5859.
SENSITIVITY OF FRESH AND CULTURED OVARIAN TUMOR-CELLS TO TUMOR NECROSIS FACTOR, INTERFERON-ALPHA-2, AND OK-432 Nio, Y., ZIGHELBOIM, J., Berek, J. S., & Bonavida, B. (1988). SENSITIVITY OF FRESH AND CULTURED OVARIAN TUMOR-CELLS TO TUMOR NECROSIS FACTOR, INTERFERON-ALPHA-2, AND OK-432. CANCER IMMUNOLOGY IMMUNOTHERAPY, 27(3), 246-254.
PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS WITH PELVIC MASSES - DISCRIMINATION OF BENIGN FROM MALIGNANT DISEASE Malkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., & RITTS, R. E. (1988). PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS WITH PELVIC MASSES - DISCRIMINATION OF BENIGN FROM MALIGNANT DISEASE. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 159(2), 341-346.
IMMUNOLOGICAL CONTROL OF OVARIAN-CANCER ZIGHELBOIM, J., Nio, Y., Berek, J. S., & Bonavida, B. (1988). IMMUNOLOGICAL CONTROL OF OVARIAN-CANCER. NATURAL IMMUNITY AND CELL GROWTH REGULATION, 7(4), 216-225.
Uterine corpus and cervical cancer. Berek, J. S., Hacker, N. F., Hatch, K. D., & Young, R. C. (1988). Uterine corpus and cervical cancer. Current problems in cancer, 12(2), 61-131.
UTERINE CORPUS AND CERVICAL-CANCER Berek, J. S., Hatch, K. D., Hacker, N. F., & Young, R. C. (1988). UTERINE CORPUS AND CERVICAL-CANCER. CURRENT PROBLEMS IN CANCER, 12(2), 65-129.
CONTROVERSIES IN THE MANAGEMENT OF CERVICAL ADENOCARCINOMA Brand, E., Berek, J. S., & Hacker, N. F. (1988). CONTROVERSIES IN THE MANAGEMENT OF CERVICAL ADENOCARCINOMA. OBSTETRICS AND GYNECOLOGY, 71(2), 261-269.
Minimal cervical cancer: definition and histology. Fu, Y. S., & Berek, J. S. (1988). Minimal cervical cancer: definition and histology. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer, 106, 47-56.
INTRAPERITONEAL CISPLATINUM AS SALVAGE THERAPY FOR REFRACTORY EPITHELIAL OVARIAN-CANCER Hacker, N. F., Berek, J. S., Pretorius, R. G., Zuckerman, J., Eisenkop, S., & Lagasse, L. D. (1987). INTRAPERITONEAL CISPLATINUM AS SALVAGE THERAPY FOR REFRACTORY EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 70(5), 759-764.
RHABDOMYOSARCOMA OF THE UTERINE CERVIX - SARCOMA BOTRYOIDES Brand, E., Berek, J. S., Nieberg, R. K., & Hacker, N. F. (1987). RHABDOMYOSARCOMA OF THE UTERINE CERVIX - SARCOMA BOTRYOIDES. CANCER, 60(7), 1552-1560.
DISTANT METASTASES IN EPITHELIAL OVARIAN-CARCINOMA Dauplat, J., Hacker, N. F., Nieberg, R. K., Berek, J. S., Rose, T. P., & Sagae, S. (1987). DISTANT METASTASES IN EPITHELIAL OVARIAN-CARCINOMA. CANCER, 60(7), 1561-1566.
PROGNOSTIC-SIGNIFICANCE OF DNA PLOIDY AND MORPHOMETRIC ANALYSES OF ADENOCARCINOMA OF THE UTERINE CERVIX Fu, Y. S., Hall, T. L., Berek, J. S., Hacker, N. F., & Reagan, J. W. (1987). PROGNOSTIC-SIGNIFICANCE OF DNA PLOIDY AND MORPHOMETRIC ANALYSES OF ADENOCARCINOMA OF THE UTERINE CERVIX. ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 9(1), 17-24.
CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY Lavin, P. T., Knapp, R. C., MALKASIAN, G., Whitney, C. W., BEREK, J. C., & Bast, R. C. (1987). CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY. OBSTETRICS AND GYNECOLOGY, 69(2), 223-227.
Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Fu, Y. S., Berek, J. S., & Hilborne, L. H. (1987). Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Applied pathology, 5(1), 47-56.
INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., & ZIGHELBOIM, J. (1986). INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. SEMINARS IN ONCOLOGY, 13(3), 61-71.
HUMAN PAPILLOMAVIRUS DEOXYRIBONUCLEIC-ACID IN ADENOCARCINOMA AND ADENOSQUAMOUS CARCINOMA OF THE UTERINE CERVIX Smotkin, D., Berek, J. S., Fu, Y. S., Hacker, N. F., Major, F. J., & WETTSTEIN, F. O. (1986). HUMAN PAPILLOMAVIRUS DEOXYRIBONUCLEIC-ACID IN ADENOCARCINOMA AND ADENOSQUAMOUS CARCINOMA OF THE UTERINE CERVIX. OBSTETRICS AND GYNECOLOGY, 68(2), 241-244.
THE CA 125 ASSAY AS A PREDICTOR OF CLINICAL RECURRENCE IN EPITHELIAL OVARIAN-CANCER Niloff, J. M., Knapp, R. C., Lavin, P. T., Malkasian, G. D., Berek, J. S., & Bast, R. C. (1986). THE CA 125 ASSAY AS A PREDICTOR OF CLINICAL RECURRENCE IN EPITHELIAL OVARIAN-CANCER. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 155(1), 56-60.
CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY Heintz, A. Pm., Hacker, N. F., Berek, J. S., Rose, T. P., Munoz, A. K., & Lagasse, L. D. (1986). CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY. OBSTETRICS AND GYNECOLOGY, 67(6), 783-788.
CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS Berek, J. S., Knapp, R. C., Malkasian, G. D., Lavin, P. T., Whitney, C., & Bast, R. C. (1986). CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS. OBSTETRICS AND GYNECOLOGY, 67(5), 685-689.
NUCLEAR DEOXYRIBONUCLEIC-ACID HETEROGENEITY OF OVARIAN BORDERLINE MALIGNANT SEROUS TUMORS Fu, Y. S., Ro, J., Reagan, J. W., Hall, T. L., & Berek, J. (1986). NUCLEAR DEOXYRIBONUCLEIC-ACID HETEROGENEITY OF OVARIAN BORDERLINE MALIGNANT SEROUS TUMORS. OBSTETRICS AND GYNECOLOGY, 67(4), 478-482.
PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY Thigpen, J. T., Blessing, J. A., Homesley, H. D., Berek, J. S., & Creasman, W. T. (1986). PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. GYNECOLOGIC ONCOLOGY, 23(1), 101-104.
ANTITUMOR AND IMMUNOLOGICAL EFFECTS OF A PYRIDINE-EXTRACTED FRACTION OF PROPIONIBACTERIUM-ACNES Lichtenstein, A., & Berek, J. (1986). ANTITUMOR AND IMMUNOLOGICAL EFFECTS OF A PYRIDINE-EXTRACTED FRACTION OF PROPIONIBACTERIUM-ACNES. CANCER IMMUNOLOGY IMMUNOTHERAPY, 22(1), 24-30.
INTRAPERITONEAL RECOMBINANT INTERFERON-ALPHA-2 FOR SALVAGE IMMUNOTHERAPY IN PERSISTENT EPITHELIAL OVARIAN-CANCER Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., & ZIGHELBOIM, J. (1985). INTRAPERITONEAL RECOMBINANT INTERFERON-ALPHA-2 FOR SALVAGE IMMUNOTHERAPY IN PERSISTENT EPITHELIAL OVARIAN-CANCER. CANCER TREATMENT REVIEWS, 12, 23-32.
SYNERGISTIC EFFECTS OF COMBINATION SEQUENTIAL IMMUNOTHERAPIES IN A MURINE OVARIAN-CANCER MODEL Berek, J. S., Lichtenstein, A. K., Knox, R. M., Jung, T. S., Rose, T. P., & ZIGHELBOIM, J. (1985). SYNERGISTIC EFFECTS OF COMBINATION SEQUENTIAL IMMUNOTHERAPIES IN A MURINE OVARIAN-CANCER MODEL. CANCER RESEARCH, 45(9), 4215-4218.
INTRAPERITONEAL IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM Berek, J. S., Knapp, R. C., Hacker, N. F., Lichtenstein, A., Jung, T., & Bast, R. C. (1985). INTRAPERITONEAL IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 152(8), 1003-1010.
WHOLE ABDOMINAL RADIATION AS SALVAGE THERAPY FOR EPITHELIAL OVARIAN-CANCER Hacker, N. F., Berek, J. S., Burnison, C. M., Heintz, A. Pm., Juillard, G. Jf., & Lagasse, L. D. (1985). WHOLE ABDOMINAL RADIATION AS SALVAGE THERAPY FOR EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 65(1), 60-66.
INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., & ZIGHELBOIM, J. (1985). INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. CANCER RESEARCH, 45(9), 4447-4453.
ADENOCARCINOMA OF THE UTERINE CERVIX - HISTOLOGIC VARIABLES ASSOCIATED WITH LYMPH-NODE METASTASIS AND SURVIVAL Berek, J. S., Hacker, N. F., Fu, Y. S., SOKALE, J. R., LEUCHTER, R. C., & Lagasse, L. D. (1985). ADENOCARCINOMA OF THE UTERINE CERVIX - HISTOLOGIC VARIABLES ASSOCIATED WITH LYMPH-NODE METASTASIS AND SURVIVAL. OBSTETRICS AND GYNECOLOGY, 65(1), 46-52.
NATURAL-KILLER INHIBITORY SUBSTANCE PRODUCED BY THE PERITONEAL-CELLS OF PATIENTS WITH OVARIAN-CANCER Lichtenstein, A. K., Berek, J., & ZIGHELBOIM, J. (1985). NATURAL-KILLER INHIBITORY SUBSTANCE PRODUCED BY THE PERITONEAL-CELLS OF PATIENTS WITH OVARIAN-CANCER. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 74(2), 349-355.
ROLE OF INFLAMMATORY NEUTROPHILS IN ANTITUMOR EFFECTS INDUCED BY INTRAPERITONEAL ADMINISTRATION OF CORYNEBACTERIUM-PARVUM IN MICE Lichtenstein, A. K., Berek, J., Kahle, J., & ZIGHELBOIM, J. (1984). ROLE OF INFLAMMATORY NEUTROPHILS IN ANTITUMOR EFFECTS INDUCED BY INTRAPERITONEAL ADMINISTRATION OF CORYNEBACTERIUM-PARVUM IN MICE. CANCER RESEARCH, 44(11), 5118-5123.
SUCCESSFUL IMMUNOTHERAPY WITH INTRAPERITONEAL CORNYEBACTERIUM-PARVUM IN A MURINE OVARIAN-CANCER MODEL IS ASSOCIATED WITH THE RECRUITMENT OF TUMOR-LYTIC NEUTROPHILS INTO THE PERITONEAL-CAVITY Lichtenstein, A. K., Kahle, J., Berek, J., & ZIGHELBOIM, J. (1984). SUCCESSFUL IMMUNOTHERAPY WITH INTRAPERITONEAL CORNYEBACTERIUM-PARVUM IN A MURINE OVARIAN-CANCER MODEL IS ASSOCIATED WITH THE RECRUITMENT OF TUMOR-LYTIC NEUTROPHILS INTO THE PERITONEAL-CAVITY. JOURNAL OF IMMUNOLOGY, 133(1), 519-526.
INDIVIDUALIZATION OF TREATMENT FOR STAGE-I SQUAMOUS-CELL VULVAR CARCINOMA Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Leuchter, R. S. (1984). INDIVIDUALIZATION OF TREATMENT FOR STAGE-I SQUAMOUS-CELL VULVAR CARCINOMA. OBSTETRICS AND GYNECOLOGY, 63(2), 155-162.
PREOPERATIVE RADIATION-THERAPY FOR LOCALLY ADVANCED VULVAR CANCER Hacker, N. F., Berek, J. S., Juillard, G. Jf., & Lagasse, L. D. (1984). PREOPERATIVE RADIATION-THERAPY FOR LOCALLY ADVANCED VULVAR CANCER. CANCER, 54(10), 2056-2061.
IMMUNOTHERAPY WITH BIOCHEMICALLY DISSOCIATED FRACTIONS OF PROPIONIBACTERIUM ACNES IN A MURINE OVARIAN-CANCER MODEL Berek, J. S., Cantrell, J. L., Lichtenstein, A. K., Hacker, N. F., Knox, R. M., & ZIGHELBOIM, J. (1984). IMMUNOTHERAPY WITH BIOCHEMICALLY DISSOCIATED FRACTIONS OF PROPIONIBACTERIUM ACNES IN A MURINE OVARIAN-CANCER MODEL. CANCER RESEARCH, 44(5), 1871-1875.
2ND-LOOK LAPAROTOMY IN STAGE-III EPITHELIAL OVARIAN-CANCER - CLINICAL-VARIABLES ASSOCIATED WITH DISEASE STATUS Berek, J. S., Hacker, N. F., Lagasse, L. D., Poth, T., Resnick, B., & Nieberg, R. K. (1984). 2ND-LOOK LAPAROTOMY IN STAGE-III EPITHELIAL OVARIAN-CANCER - CLINICAL-VARIABLES ASSOCIATED WITH DISEASE STATUS. OBSTETRICS AND GYNECOLOGY, 64(2), 207-212.
RECTOSIGMOID COLECTOMY AND REANASTOMOSIS TO FACILITATE RESECTION OF PRIMARY AND RECURRENT GYNECOLOGIC CANCER Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1984). RECTOSIGMOID COLECTOMY AND REANASTOMOSIS TO FACILITATE RESECTION OF PRIMARY AND RECURRENT GYNECOLOGIC CANCER. OBSTETRICS AND GYNECOLOGY, 64(5), 715-720.
VAGINAL RECONSTRUCTION PERFORMED SIMULTANEOUSLY WITH PELVIC EXENTERATION Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1984). VAGINAL RECONSTRUCTION PERFORMED SIMULTANEOUSLY WITH PELVIC EXENTERATION. OBSTETRICS AND GYNECOLOGY, 63(3), 318-323.
LYMPHOCYTE CYTO-TOXICITY IN THE PERITONEAL-CAVITY AND BLOOD OF PATIENTS WITH OVARIAN-CANCER Berek, J. S., Bast, R. C., Lichtenstein, A., Hacker, N. F., Spina, C. A., & ZIGHELBOIM, J. (1984). LYMPHOCYTE CYTO-TOXICITY IN THE PERITONEAL-CAVITY AND BLOOD OF PATIENTS WITH OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 64(5), 708-714.
ACTIVATION OF PERITONEAL LYMPHOCYTE CYTO-TOXICITY IN PATIENTS WITH OVARIAN-CANCER BY INTRAPERITONEAL TREATMENT WITH CORYNEBACTERIUM-PARVUM Lichtenstein, A., Berek, J., Bast, R., Spina, C., Hacker, N., & ZIGHELBOIM, J. (1984). ACTIVATION OF PERITONEAL LYMPHOCYTE CYTO-TOXICITY IN PATIENTS WITH OVARIAN-CANCER BY INTRAPERITONEAL TREATMENT WITH CORYNEBACTERIUM-PARVUM. JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 3(4), 371-378.
ESTROGEN AND PROGESTERONE RECEPTORS IN OVARIAN NEOPLASMS Ford, L. C., Berek, J. S., Lagasse, L. D., Hacker, N. F., Heins, Y., & DELANGE, R. J. (1983). ESTROGEN AND PROGESTERONE RECEPTORS IN OVARIAN NEOPLASMS. GYNECOLOGIC ONCOLOGY, 15(3), 299-304.
ESTROGEN AND PROGESTERONE-RECEPTOR SITES IN MALIGNANCIES OF THE UTERINE CERVIX, VAGINA, AND VULVA Ford, L. C., Berek, J. S., Lagasse, L. D., Hacker, N. F., HEINS, Y. L., & DELANGE, R. J. (1983). ESTROGEN AND PROGESTERONE-RECEPTOR SITES IN MALIGNANCIES OF THE UTERINE CERVIX, VAGINA, AND VULVA. GYNECOLOGIC ONCOLOGY, 15(1), 27-31.
MANAGEMENT OF REGIONAL LYMPH-NODES AND THEIR PROGNOSTIC INFLUENCE IN VULVAR CANCER Hacker, N. F., Berek, J. S., Lagasse, L. D., Leuchter, R. S., & MOORE, J. G. (1983). MANAGEMENT OF REGIONAL LYMPH-NODES AND THEIR PROGNOSTIC INFLUENCE IN VULVAR CANCER. OBSTETRICS AND GYNECOLOGY, 61(4), 408-412.
INTRAPERITONEAL IMMUNOTHERAPY OF HUMAN OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM Bast, R. C., Berek, J. S., Obrist, R., Griffiths, C. T., Berkowitz, R. S., & Knapp, R. C. (1983). INTRAPERITONEAL IMMUNOTHERAPY OF HUMAN OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM. CANCER RESEARCH, 43(3), 1395-1401.
SUPERFICIALLY INVASIVE VULVAR CANCER WITH NODAL METASTASES Hacker, N. F., Nieberg, R. K., Berek, J. S., Leuchter, R. S., LUCAS, W. E., & Lagasse, L. D. (1983). SUPERFICIALLY INVASIVE VULVAR CANCER WITH NODAL METASTASES. GYNECOLOGIC ONCOLOGY, 15(1), 65-77.
PRIMARY CYTOREDUCTIVE SURGERY FOR EPITHELIAL OVARIAN-CANCER Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983). PRIMARY CYTOREDUCTIVE SURGERY FOR EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 61(4), 413-420.
SURVIVAL OF PATIENTS FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY IN OVARIAN-CANCER Berek, J. S., Hacker, N. F., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983). SURVIVAL OF PATIENTS FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY IN OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 61(2), 189-193.
DELAYED VAGINAL RECONSTRUCTION IN THE FIBROTIC PELVIS FOLLOWING RADIATION OR PREVIOUS RECONSTRUCTION Berek, J. S., Hacker, N. F., Lagasse, L. D., & Smith, M. L. (1983). DELAYED VAGINAL RECONSTRUCTION IN THE FIBROTIC PELVIS FOLLOWING RADIATION OR PREVIOUS RECONSTRUCTION. OBSTETRICS AND GYNECOLOGY, 61(6), 743-748.
MICROINVASIVE CARCINOMA OF THE VULVA Hacker, N. F., Berek, J. S., Lagasse, L. D., & Nieberg, R. K. (1983). MICROINVASIVE CARCINOMA OF THE VULVA. OBSTETRICS AND GYNECOLOGY, 62(1), 134-135.
LAPAROSCOPY IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA Berek, J. S., & Hacker, N. F. (1983). LAPAROSCOPY IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA. CLINICS IN OBSTETRICS AND GYNAECOLOGY, 10(2), 213-222.
PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA Pretorius, R. G., Hacker, N. F., Berek, J. S., Ford, L. C., Hoeschele, J. D., & Lagasse, L. D. (1983). PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA. CANCER TREATMENT REPORTS, 67(12), 1085-1092.
MANAGEMENT OF POST-EXENTERATION PERINEAL HERNIAS BY MYOCUTANEOUS AXIAL FLAPS Leuchter, R. S., Lagasse, L. D., Hacker, N. F., & Berek, J. S. (1982). MANAGEMENT OF POST-EXENTERATION PERINEAL HERNIAS BY MYOCUTANEOUS AXIAL FLAPS. GYNECOLOGIC ONCOLOGY, 14(1), 15-22.
PRIMARY-CARCINOMA OF THE BARTHOLIN GLAND - A REPORT OF 14 CASES AND REVIEW OF THE LITERATURE Leuchter, R. S., Hacker, N. F., Voet, R. L., Berek, J. S., Townsend, D. E., & Lagasse, L. D. (1982). PRIMARY-CARCINOMA OF THE BARTHOLIN GLAND - A REPORT OF 14 CASES AND REVIEW OF THE LITERATURE. OBSTETRICS AND GYNECOLOGY, 60(3), 361-368.
LOWER URINARY-TRACT RESECTION AS PART OF CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER Berek, J. S., Hacker, N. F., Lagasse, L. D., & Leuchter, R. S. (1982). LOWER URINARY-TRACT RESECTION AS PART OF CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 13(1), 87-92.
LEVATOR ANI TRANSPOSITION FOR ANAL INCOMPETENCE SECONDARY TO SPHINCTER DAMAGE Berek, J. S., Lagasse, L. D., Hacker, N. F., & Leuchter, R. S. (1982). LEVATOR ANI TRANSPOSITION FOR ANAL INCOMPETENCE SECONDARY TO SPHINCTER DAMAGE. OBSTETRICS AND GYNECOLOGY, 59(1), 108-112.
RECENT PROGRESS IN THE TREATMENT OF EPITHELIAL OVARIAN MALIGNANCY Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1982). RECENT PROGRESS IN THE TREATMENT OF EPITHELIAL OVARIAN MALIGNANCY. WESTERN JOURNAL OF MEDICINE, 137(4), 273-277.
CARCINOMA OF THE CERVIX ASSOCIATED WITH PREGNANCY Hacker, N. F., Berek, J. S., Lagasse, L. D., Charles, E. H., SAVAGE, E. W., & MOORE, J. G. (1982). CARCINOMA OF THE CERVIX ASSOCIATED WITH PREGNANCY. OBSTETRICS AND GYNECOLOGY, 59(6), 735-747.
RADICAL VULVECTOMY AND BILATERAL INGUINAL LYMPHADENECTOMY THROUGH SEPARATE GROIN INCISIONS Hacker, N. F., Leuchter, R. S., Berek, J. S., CASTALDO, T. W., & Lagasse, L. D. (1981). RADICAL VULVECTOMY AND BILATERAL INGUINAL LYMPHADENECTOMY THROUGH SEPARATE GROIN INCISIONS. OBSTETRICS AND GYNECOLOGY, 58(5), 574-579.
ADENOCARCINOMA OF THE UTERINE CERVIX Berek, J. S., CASTALDO, T. W., Hacker, N. F., PETRILLI, E. S., Lagasse, L. D., & MOORE, J. G. (1981). ADENOCARCINOMA OF THE UTERINE CERVIX. CANCER, 48(12), 2734-2741.
LAPAROSCOPY FOR 2ND-LOOK EVALUATION IN OVARIAN-CANCER Berek, J. S., Griffiths, C. T., & Leventhal, J. M. (1981). LAPAROSCOPY FOR 2ND-LOOK EVALUATION IN OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 58(2), 192-198.
PERINATAL-MORTALITY IN TERM AND POST-TERM BIRTHS Stubblefield, P. G., & Berek, J. S. (1980). PERINATAL-MORTALITY IN TERM AND POST-TERM BIRTHS. OBSTETRICS AND GYNECOLOGY, 56(6), 676-682.
MASSIVE EXUDATIVE ASCITES PRODUCED FROM A TUBAL PSEUDOCYST IN CHRONIC PELVIC INFLAMMATORY DISEASE Berek, J. S., & Darney, P. D. (1979). MASSIVE EXUDATIVE ASCITES PRODUCED FROM A TUBAL PSEUDOCYST IN CHRONIC PELVIC INFLAMMATORY DISEASE. OBSTETRICS AND GYNECOLOGY, 54(4), 490-492.
ANATOMIC AND CLINICAL CORRELATES OF UTERINE PERFORATION Berek, J. S., & Stubblefield, P. G. (1979). ANATOMIC AND CLINICAL CORRELATES OF UTERINE PERFORATION. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 135(2), 181-184.
EVALUATION OF A BALLOON DILATOR BEFORE 2ND-TRIMESTER ABORTION BY VACUUM CURETTAGE Stubblefield, P. G., Frederiksen, M. C., Berek, J. S., GATTER, M. A., Kayman, D. J., & BORTEN, M. (1979). EVALUATION OF A BALLOON DILATOR BEFORE 2ND-TRIMESTER ABORTION BY VACUUM CURETTAGE. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 135(2), 199-201.

View All 263 Publications

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

5.0

Friendliness

5.0

Friendliness

4.9

Recommended to others

4.9

Recommended to others

5.0

Explanations

5.0

Explanations

4.9

Listens

4.9

Listens

4.9

Includes you in decisions

4.9

Includes you in decisions

5.0

Clear Communication

5.0

Clear Communication

4.9

Confidence in your doctor

4.9

Confidence in your doctor

4.8

Wait times

4.8

Wait times

SHC Patient, Feb 2015

Wonderful doctor!

SHC Patient, Feb 2015

I love seeing Dr. Berek. He is wonderful.

SHC Patient, Jan 2015

Dr. Berek is a kind, caring person and the very finest of doctors.

SHC Patient, Jul 2014

My confidence in Dr. Berek goes beyond "very good."

SHC Patient, Apr 2014

My problem is not with Dr. Berek's care for me during the consultation but rather the complete lack of communication from his asst. on the follow up and of providing me any written information as requested.

Patient Comments

Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

SHC Patient, Feb 2015

Wonderful doctor!

SHC Patient, Feb 2015

I love seeing Dr. Berek. He is wonderful.

SHC Patient, Jan 2015

Dr. Berek is a kind, caring person and the very finest of doctors.

SHC Patient, Jul 2014

My confidence in Dr. Berek goes beyond "very good."

SHC Patient, Apr 2014

Stay Connected. Manage Your Care.

WELCOME BACK

Guest Services

PHYSICIAN HELPLINE

REFER A PATIENT

Jonathan S. Berek, MD, MMS